Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Antibiotic kills pathogens without resistance

By R&D Editors | January 9, 2015

For years, pathogens’ resis­tance to antibi­otics has put them one step ahead of researchers, which is causing a public health crisis, according to Northeastern Uni­v. Dis­tin­guished Pro­f. Kim Lewis. But in new research, Lewis and his col­leagues present a newly dis­cov­ered antibi­otic that elimi­nates pathogens without encoun­tering any detectable resistance—a finding that chal­lenges long-​​held sci­en­tific beliefs and holds great promise for treating chronic infec­tions like tuber­cu­losis and those caused by MRSA.

The research is pub­lished in Nature.

North­eastern researchers’ pio­neering work to develop a novel method for growing uncul­tured bac­teria led to the dis­covery of the antibi­otic, called teixobactin, and Lewis’ laboratory played a key role in analyzing and testing the com­pound for resis­tance from pathogens. Lewis, who is the paper’s lead author, said this marks the first dis­covery of an antibi­otic to which resis­tance by muta­tions of pathogens have not been identified.

Lewis and North­eastern biology pro­fessor Slava Epstein co-​​authored the paper with col­leagues from the Uni­v. of Bonn in Ger­many, Novo­Bi­otic Phar­ma­ceu­ti­cals in Cam­bridge, Mass­., and Selcia Lim­ited in the U.K.

The research team says teixobactin’s dis­covery presents a promising new oppor­tu­nity to treat chronic infec­tions caused by staphy­lo­coccus aureus, or MRSA, that are highly resis­tant to antibi­otics, as well as tuber­cu­losis, which involves a com­bi­na­tion of ther­a­pies with neg­a­tive side effects.

The screening of soil microor­gan­isms has pro­duced most antibi­otics, but only 1% of them will grow in the laboratory, and this lim­ited resource was over­mined in the 1960s, Lewis explained. He and Epstein spent years seeking to address this problem by tap­ping into a new source of antibi­otics beyond those cre­ated by syn­thetic means: uncul­tured bac­teria, which make up 99% of all species in external environments. They devel­oped a novel method for growing uncul­tured bac­teria in their nat­ural environment, which led to the founding of Novo­Bi­otic. Their approach involves the iChip, a minia­ture device Epstein’s team cre­ated that can iso­late and help grow single cells in their nat­ural envi­ron­ment and thereby pro­vides researchers with much improved access to uncul­tured bac­teria. Novo­Bi­otic has since assem­bled about 50,000 strains of uncul­tured bac­teria and dis­cov­ered 25 new antibi­otics, of which teixobactin is the latest and most inter­esting, Lewis said.

The antibi­otic was dis­cov­ered during a rou­tine screening for antimi­cro­bial mate­rial using this method. Lewis then tested the com­pound for resis­tance devel­op­ment and did not find mutant MRSA or Mycobac­terium tuber­cu­losis resis­tant to teixobactin, which was found to block sev­eral different tar­gets in the cell wall syn­thesis pathway.

“Our impres­sion is that nature pro­duced a com­pound that evolved to be free of resis­tance,” Lewis said. “This chal­lenges the dogma that we’ve oper­ated under that bac­teria will always develop resis­tance. Well, maybe not in this case.”

Gerard Wright, a pro­fessor in the Dept. of Bio­chem­istry and Bio­med­ical Sci­ences at McMaster Uni­v. and who was not involved in this research, exam­ined the team’s work in a sep­a­rate article for Nature published in con­cert with the new research paper. In his article, Wright noted that while it remains to be seen whether other mech­a­nisms for resis­tance against teixobactin exist in the envi­ron­ment, the team’s work could lead to iden­ti­fying “other ‘resistance-​​light’ antibiotics.”

“(The researchers’) work offers hope that inno­va­tion and cre­ativity can com­bine to solve the antibi­otics crisis,” Wright wrote.

Going for­ward, the research team hopes to develop teixobactin into a drug.

In 2013, Lewis revealed ground­breaking research in a sep­a­rate paper pub­lished by Nature that presented a novel approach to treat and elim­i­nate MRSA—the so-​​called “superbug” that infects 1 million Amer­i­cans annu­ally. Lewis and his team dis­cov­ered a way to destroy the dor­mant persister cells, which are key to the suc­cess of chronic infec­tions caused by MRSA.

Lewis said this latest research lays new ground to advance his inno­v­a­tive work on treating MRSA and other chronic infections.

Source: Northeastern Univ.

Related Articles Read More >

Floating solar mats clean polluted water — and generate power
New AI model offers faster, adaptive CO₂ retrieval from satellite data
8 major R&D moves this week: Samsung invests record $24B while Porsche cuts 3,900 jobs
Ex-Google AI team launches “Generation,” an AI-driven fragrance venture
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE